Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to Triple Therapy

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Tiotropium and Olodaterol (Tio+Olo)
Drug: Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS)

First Posted Date: 2019-12-03

Last Posted Date: 2021-11-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 27190

Registration Number: NCT04184297

Locations: 🇺🇸
HealthCore, Inc., Andover, Massachusetts, United States

Real-world Study Comparing the Adherence and Effectiveness of Linagliptin vs. Acarbose

Terminated

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Acarbose
Drug: Linagliptin

First Posted Date: 2019-11-29

Last Posted Date: 2022-06-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 85

Registration Number: NCT04180813

Locations: 🇨🇳
Huai'an first people's hospital, Huai'an, China
🇨🇳
Dongying People's Hospital, Dongying, China
🇨🇳
Zhongda Hospital Southeast University, Nanjing, China

and more 7 locations

The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib

Completed

Conditions: Non-squamous, Non-Small Cell Lung Cancer

Interventions: Drug: Afatinib (Gi(l)otrif®)
Drug: Erlotinib (Tarceva®)
Drug: Osimertinib (Tagrisso®)
Drug: Gefitinib (IRESSA®)

First Posted Date: 2019-11-27

Last Posted Date: 2023-05-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 462

Registration Number: NCT04179890

Locations: 🇬🇧
Royal Marsden Hospital, London, United Kingdom

A Study in People With Normal Kidney Function and People With Reduced Kidney Function to Test How BI 764198 is Processed in the Body

Phase 1

Completed

Conditions: Healthy
Chronic Kidney Disease

Interventions: Drug: BI 764198

First Posted Date: 2019-11-25

Last Posted Date: 2020-12-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 28

Registration Number: NCT04176536

Locations: 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Germany

A Study in South Korea Using Medical Records to Look at Different Treatments for Chronic Obstructive Airway Disease (COPD)

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Long-acting Muscarinic Antagonists (LAMA)
Drug: Inhaled corticosteroid (ICS)/Long-acting Beta Agonists (LABA)

First Posted Date: 2019-11-21

Last Posted Date: 2022-04-07

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 9284

Registration Number: NCT04172701

Locations: 🇰🇷
Konkuk University Medical Center, Seoul, Korea, Republic of

A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure

Phase 3

Completed

Conditions: Heart Failure

Interventions: Drug: Empagliflozin
Drug: Placebo to Empagliflozin

First Posted Date: 2019-11-08

Last Posted Date: 2022-07-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 530

Registration Number: NCT04157751

Locations: 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸
Grady Memorial Hospital, Atlanta, Georgia, United States
🇨🇦
Toronto General Hospital, Toronto, Ontario, Canada

and more 115 locations

A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: BI 456906
Drug: Placebo
Drug: Semaglutide

First Posted Date: 2019-11-06

Last Posted Date: 2022-11-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 413

Registration Number: NCT04153929

Locations: 🇺🇸
Javara Research, Sugar Land, Texas, United States
🇺🇸
San Marcus Research Clinic, Inc., Miami, Florida, United States
🇬🇧
Burbage Surgery, Burbage, Hinkley, United Kingdom

and more 74 locations

A Trial to Find the Safe Dose for BI 905681 in Patients With Incurable Tumours or Tumours That Have Spread

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: BI 905681

First Posted Date: 2019-11-01

Last Posted Date: 2023-11-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 21

Registration Number: NCT04147247

Locations: 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Evaluation of Photosafety of BI 730357 Compared to Placebo and the Known Photosensitizing Agent Ciprofloxacin

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 730357
Drug: Placebo to match BI 730357
Drug: Ciprofloxacin

First Posted Date: 2019-11-01

Last Posted Date: 2023-07-17

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 85

Registration Number: NCT04147260

Locations: 🇺🇸
TKL Research, Inc., Fair Lawn, New Jersey, United States

A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors)

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: BI 1387446
Drug: BI 754091

First Posted Date: 2019-11-01

Last Posted Date: 2024-11-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 39

Registration Number: NCT04147234

Locations: 🇪🇸
Hospital Vall d'Hebron-Barcelona-47683, Barcelona, Spain
🇺🇸
Froedtert and The Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇪🇸
CIO Clara Campal, Madrid, Spain

and more 4 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy